Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: COVID-19 infection is associated with significant morbidity in systemic lupus erythematosus but is potentially preventable by vaccination, although the impact of the myriad vaccines among SLE patients is not established. We aimed to assess the effectiveness, efficacy, acceptance and safety of COVID-19 vaccination in SLE.
Methods: We performed a systematic review of PubMed, EMBASE, CENTRAL, and Scopus publications until 8 June 2022 without language, publication year or publication status restrictions. Reports with fewer than 5 patients or incomplete information on study outcomes were excluded. Risk of bias was assessed, and results reported according to the PRISMA 2020 guidelines.
Results: We identified 32 studies (34 reports) comprising 8269 individuals with SLE. Post-vaccine COVID-19 infections ranged from 0 to 17% in 6 studies (5065 patients), while humoral and cellular immunogenicity was evaluated in 17 studies (976 patients) and 5 studies (112 patients), respectively. The pooled seropositivity rate was 81.1% (95% CI: 72.6, 88.5%, I2 = 85%, P < 0.01), with significant heterogeneity and higher rates for mRNA vaccines compared with non-mRNA vaccines. Adverse events and specifically lupus flares were examined in 20 studies (3853 patients) and 13 studies (2989 patients), respectively. Severe adverse events and moderate to severe lupus flares were infrequent. The pooled vaccine acceptance rate was 67.0% (95% CI: 45.2, 85.6%, I2=98%, P < 0.01) from 8 studies (1348 patients), with greater acceptance in older patients.
Conclusion: Among SLE patients, post-vaccine COVID-19 infections, severe flares, and adverse events were infrequent, while pooled seropositivity and acceptance were high, with significant heterogeneity. These results may inform shared decision-making on vaccination during the ongoing COVID-19 pandemic.
Trial Registration: PROSPERO, https://www.crd.york.ac.uk/PROSPERO/, CRD42021233366.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620290 | PMC |
| http://dx.doi.org/10.1093/rheumatology/keac604 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of Receptor-Binding Domain (RBD)-Loaded PEG-PCL Nanoparticle Formulations Against SARS-CoV-2.
Macromol Biosci
September 2025
Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Tandogan, Ankara, Turkey.
The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has highlighted the critical need for safe and effective vaccines. In this study, subunit nanovaccine formulations were developed using the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein encapsulated in polymeric nanoparticles composed of poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-PCL). Two surfactants, poly(vinyl alcohol) (PVA) and sodium cholate (SC), were evaluated during formulation via a modified water-in-oil-in-water (w/o/w) emulsion-solvent evaporation method.
View Article and Find Full Text PDFInfluenza and COVID-19 Multicomponent Vaccine in Adults-Reply.
JAMA
September 2025
Moderna, Inc, Cambridge, Massachusetts.
Influenza and COVID-19 Multicomponent Vaccine in Adults.
JAMA
September 2025
Department of Pulmonary and Critical Care Medicine, Xiangtan Central Hospital, Xiangtan, China.
Breakthrough SARS-CoV-2 outcomes in immune-disordered people during the Omicron era: a prospective cohort study.
BMJ Public Health
August 2025
Epidemiology and Data Management Unit, Division of Intramural Research, National Institute of Allergy and Infectious Diseases Division of Intramural Research, Bethesda, Maryland, USA.
Introduction: Immune-deficient/disordered people (IDP) elicit a less robust immune response to COVID-19 vaccination than the general US population. Despite millions of IDP at presumed elevated risk, few population-level studies of IDP have been conducted in the Omicron era to evaluate breakthrough infection-related outcomes.
Methods: We followed a prospective cohort of 219 IDP and 63 healthy volunteers (HV) in the USA from April 2021 (Alpha variant peak) to July 2023 (Omicron XBB variant peak).
Understanding influenza-like illness dynamics in Jiangsu, China: impacts of COVID-19 control measures and meteorological factors on the population health during 2018-2023.
BMJ Public Health
September 2025
School of Public Health, Nanjing Medical University, Nanjing, China.
Background: Since the emergence of the COVID-19 pandemic, how meteorological factors and COVID-19 control measures in China impact the transmission dynamics of influenza-like illness (ILI) across age groups remains unclear.
Objective: This study aims to explore the changes in the seasonal ILI epidemics and the effects of meteorological factors across age groups in Jiangsu, China, before the COVID-19 pandemic and after the relaxation of COVID-19 control measures.
Methods: The time-varying reproduction number ( ) and doubling time of ILI were deployed to describe the trend and iteration time of the ILI epidemic, and the effect of Chinese government response to COVID-19 on the ILI epidemic, respectively.